A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges

摘要: A single injection of four anti-HIV-1-neutralizing monoclonal antibodies blocks repeated weekly low-dose virus challenges simian/human immunodeficiency virus. This study assesses the long-term efficacy a passive antibody transfer approach for control human type 1 (HIV-1) infection. Malcolm Martin and colleagues administered intravenous injections different anti-HIV-1 neutralizing in simian/HIV intrarectal exposure model involving viral challenge demonstrate protection from infection lasting almost 6 months. Despite success potent anti-retroviral drugs controlling infection, little progress has been made generating an effective HIV-1 vaccine. Although broadly can protect mice or macaques against high-dose with HIV (SIV/HIV) chimaeric viruses (SHIVs) respectively1,2,3,4,5,6,7,8, not examined. Here we show, on basis relatively conferred by hepatitis immune globulin, (20 mg kg−1) (VRC01, VRC01-LS, 3BNC117, 10-1074 (refs 9, 10, 11, 12)) blocking clade B SHIVAD8. Compared animals, which required two to six (median = 3) infusion prevented acquisition up 23 challenges. effect depended potency half-life. The highest levels plasma-neutralizing activity and, correspondingly, longest were found monkeys more 3BNC117 (median = 13 12.5 weeks, respectively). VRC01, showed lower activity, protected shorter time (median = 8 weeks). introduction mutation that extends half-life into crystallizable fragment (Fc) domain VRC01 increased median 8 14.5 weeks. If populations at high risk transmission, such immunoprophylaxis regimen could have major impact transmission.